.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents and clinical trials in dozens of countries

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
AstraZeneca
US Army
Healthtrust
Accenture
Federal Trade Commission
Novartis
Cantor Fitzgerald
Merck

Generated: June 23, 2017

DrugPatentWatch Database Preview

STAXYN Drug Profile

« Back to Dashboard

Which patents cover Staxyn, and what generic Staxyn alternatives are available?

Staxyn is a drug marketed by Bayer Hlthcare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-nine patent family members in fifty-three countries.

The generic ingredient in STAXYN is vardenafil hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the vardenafil hydrochloride profile page.

Summary for Tradename: STAXYN

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list94
Patent Applications: see list1,810
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:STAXYN at DailyMed

Pharmacology for Tradename: STAXYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Hlthcare
STAXYN
vardenafil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010ABRXYesYes8,613,950► SubscribeY ► Subscribe
Bayer Hlthcare
STAXYN
vardenafil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010ABRXYesYes7,696,206► Subscribe ► Subscribe
Bayer Hlthcare
STAXYN
vardenafil hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL200179-001Jun 17, 2010ABRXYesYes6,362,178► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: STAXYN

Drugname Dosage Strength RLD Submissiondate
vardenafil hydrochlorideOrally Disintegrating Tablets10 mgStaxyn12/22/2011

Non-Orange Book Patents for Tradename: STAXYN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,314,8712-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors, for treatment of hypertension► Subscribe
6,566,360 2-phenyl substituted imidatriazinones as phosphodiesterase inhibitors► Subscribe
7,704,9992-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
7,122,5402-Phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
6,890,922 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: STAXYN

Country Document Number Estimated Expiration
South Korea20070110109► Subscribe
Russian Federation2481110► Subscribe
Hong Kong1067124► Subscribe
Poland201336► Subscribe
Poland194801► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Cerilliant
Baxter
McKinsey
UBS
Johnson and Johnson
Federal Trade Commission
Queensland Health
Daiichi Sankyo
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot